To further validate the efficacy of BiCisCAR T cells in a NB heterogeneous model, we used a mixture of 50% IMR5, 25% GPC2-KO IMR5, and 25% CD276-KO IMR5 cells in a metastatic mouse model (Supplemental Figure 12, A and B). Here, CD276 is linked to neuroblastoma.